Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy DOI Creative Commons
Tao Lei, Yazhuo Wang, Yuchen Zhang

et al.

Leukemia, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 25, 2024

Language: Английский

Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease DOI
Andrea R. Daamen, Peter E. Lipsky

Annals of the Rheumatic Diseases, Journal Year: 2024, Volume and Issue: 83(6), P. 696 - 699

Published: April 18, 2024

Chimeric antigen receptors (CARs) are synthetic proteins designed to direct an immune response toward a specific target and have been used in immunotherapeutic applications through the adoptive transfer of T cells genetically engineered express CARs. This technology received early attention oncology with particular success treatment B cell malignancies leading launch numerous successful clinical trials US Food Drug Administration approval several CAR-T-based therapies. Many CAR-T constructs employed, but always administered following lymphodepletion regimen. The targeting malignant has led many consider potential for using these regimens delete pathogenic autoimmune diseases. Preliminary results suggested efficacy, sample size remains small, controlled not done, role immunodepletion established, most effective identified appropriate patient subsets established.

Language: Английский

Citations

14
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach DOI
Eleonora Ghisoni, Matteo Morotti,

Apostolos Sarivalasis

et al.

Nature Reviews Clinical Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 4, 2024

Language: Английский

Citations

14
CD28 co-stimulation: novel insights and applications in cancer immunotherapy DOI
Michael T. Lotze, Scott H. Olejniczak, Dimitris Skokos

et al.

Nature reviews. Immunology, Journal Year: 2024, Volume and Issue: 24(12), P. 878 - 895

Published: July 25, 2024

Language: Английский

Citations

13
Frontiers in CAR-T cell therapy for autoimmune diseases DOI Creative Commons
Yan-Ruide Li,

Zibai Lyu,

Yuning Chen

et al.

Trends in Pharmacological Sciences, Journal Year: 2024, Volume and Issue: 45(9), P. 839 - 857

Published: Aug. 14, 2024

Chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy has demonstrated significant success in treating cancers. The potential of CAR-T cells is now being explored the context autoimmune diseases. Recent clinical trials have shown sustained and profound elimination autoreactive B by cells, leading to promising disease control with minimal safety concerns. These encouraging results inspired further investigation into applications for a broader range diseases development advanced products improved efficacy safety. In this review, we discuss mechanisms which target conditions, summarize current preclinical models, highlight ongoing trials, including design, outcomes, challenges. Additionally, limitations future directions treatment

Language: Английский

Citations

13
Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy DOI Creative Commons
Tao Lei, Yazhuo Wang, Yuchen Zhang

et al.

Leukemia, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 25, 2024

Language: Английский

Citations

13